Press releases
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
- Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program
- Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
- Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
- Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 80.46 |
---|---|
High | 80.46 |
Low | 80.46 |
Bid | 79.76 |
Offer | 80.08 |
Previous close | 80.46 |
Average volume | -- |
---|---|
Shares outstanding | 87.98m |
Free float | 83.68m |
P/E (TTM) | -- |
Market cap | 11.97bn USD |
EPS (TTM) | -8.03 USD |
Data delayed at least 15 minutes, as of Nov 09 2021.
More ▼